Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design

D. Sean Froese, Amit Michaeli, Thomas J. McCorvie, Tobias Krojer, Meitav Sasi, Esther Melaev, Amiram Goldblum, Maria Zatsepin, Alexander Lossos, Rafael Álvarez, Pablo V. Escribá, Berge A. Minassian, Frank Von Delft, Or Kakhlon, Wyatt W. Yue

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Glycogen branching enzyme 1 (GBE1) plays an essential role inglycogenbiosynthesis by generating a-1,6-glucosidic branches from α-1,4-linked glucose chains, to increase solubility of the glycogen polymer. Mutations in the GBE1 gene lead to the heterogeneous early-onset glycogen storage disorder type IV (GSDIV) or the late-onset adult polyglucosan body disease (APBD). To better understand this essential enzyme, we crystallized human GBE1 in the apo form, and in complex with a tetra- or hepta-saccharide. The GBE1 structure reveals a conservedamylase core that houses the active centre for the branching reaction and harbours almost all GSDIV andAPBDmutations. Anon-catalytic binding cleft, proximal to the site of the common APBDmutation p.Y329S,was found to bind the tetra- and hepta-saccharides andmay represent a higher-affinity site employed to anchor the complex glycogen substrate for the branching reaction. Expression of recombinant GBE1-p.Y329S resulted in drastically reduced protein yield and solubility compared with wild type, suggesting this disease allele causes protein misfolding and may be amenable to small molecule stabilization. To explore this, we generated a structural model of GBE1-p.Y329S and designed peptides ab initio to stabilize the mutation. As proof-of-principle, we evaluated treatment of one tetra-peptide, Leu-Thr-Lys-Glu, in APBD patient cells. We demonstrate intracellular transport of this peptide, its binding and stabilization of GBE1-p.Y329S, and 2-fold increased mutant enzymatic activity compared with untreated patient cells. Together, our data provide the rationale and starting point for the screening of small molecule chaperones, which could become novel therapies for this disease.

Original languageEnglish (US)
Pages (from-to)5667-5676
Number of pages10
JournalHuman Molecular Genetics
Volume24
Issue number20
DOIs
StatePublished - Jun 5 2015

Fingerprint

Glycogen Storage Disease Type IV
1,4-alpha-Glucan Branching Enzyme
Glycogen
Peptides
Solubility
Mutation
Structural Models
Polymers
Proteins
Alleles
Glucose
Enzymes
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Sean Froese, D., Michaeli, A., McCorvie, T. J., Krojer, T., Sasi, M., Melaev, E., ... Yue, W. W. (2015). Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. Human Molecular Genetics, 24(20), 5667-5676. https://doi.org/10.1093/hmg/ddv280

Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. / Sean Froese, D.; Michaeli, Amit; McCorvie, Thomas J.; Krojer, Tobias; Sasi, Meitav; Melaev, Esther; Goldblum, Amiram; Zatsepin, Maria; Lossos, Alexander; Álvarez, Rafael; Escribá, Pablo V.; Minassian, Berge A.; Von Delft, Frank; Kakhlon, Or; Yue, Wyatt W.

In: Human Molecular Genetics, Vol. 24, No. 20, 05.06.2015, p. 5667-5676.

Research output: Contribution to journalArticle

Sean Froese, D, Michaeli, A, McCorvie, TJ, Krojer, T, Sasi, M, Melaev, E, Goldblum, A, Zatsepin, M, Lossos, A, Álvarez, R, Escribá, PV, Minassian, BA, Von Delft, F, Kakhlon, O & Yue, WW 2015, 'Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design', Human Molecular Genetics, vol. 24, no. 20, pp. 5667-5676. https://doi.org/10.1093/hmg/ddv280
Sean Froese, D. ; Michaeli, Amit ; McCorvie, Thomas J. ; Krojer, Tobias ; Sasi, Meitav ; Melaev, Esther ; Goldblum, Amiram ; Zatsepin, Maria ; Lossos, Alexander ; Álvarez, Rafael ; Escribá, Pablo V. ; Minassian, Berge A. ; Von Delft, Frank ; Kakhlon, Or ; Yue, Wyatt W. / Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design. In: Human Molecular Genetics. 2015 ; Vol. 24, No. 20. pp. 5667-5676.
@article{3051a1a17d2b4bdc94cfd75f95caa23e,
title = "Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design",
abstract = "Glycogen branching enzyme 1 (GBE1) plays an essential role inglycogenbiosynthesis by generating a-1,6-glucosidic branches from α-1,4-linked glucose chains, to increase solubility of the glycogen polymer. Mutations in the GBE1 gene lead to the heterogeneous early-onset glycogen storage disorder type IV (GSDIV) or the late-onset adult polyglucosan body disease (APBD). To better understand this essential enzyme, we crystallized human GBE1 in the apo form, and in complex with a tetra- or hepta-saccharide. The GBE1 structure reveals a conservedamylase core that houses the active centre for the branching reaction and harbours almost all GSDIV andAPBDmutations. Anon-catalytic binding cleft, proximal to the site of the common APBDmutation p.Y329S,was found to bind the tetra- and hepta-saccharides andmay represent a higher-affinity site employed to anchor the complex glycogen substrate for the branching reaction. Expression of recombinant GBE1-p.Y329S resulted in drastically reduced protein yield and solubility compared with wild type, suggesting this disease allele causes protein misfolding and may be amenable to small molecule stabilization. To explore this, we generated a structural model of GBE1-p.Y329S and designed peptides ab initio to stabilize the mutation. As proof-of-principle, we evaluated treatment of one tetra-peptide, Leu-Thr-Lys-Glu, in APBD patient cells. We demonstrate intracellular transport of this peptide, its binding and stabilization of GBE1-p.Y329S, and 2-fold increased mutant enzymatic activity compared with untreated patient cells. Together, our data provide the rationale and starting point for the screening of small molecule chaperones, which could become novel therapies for this disease.",
author = "{Sean Froese}, D. and Amit Michaeli and McCorvie, {Thomas J.} and Tobias Krojer and Meitav Sasi and Esther Melaev and Amiram Goldblum and Maria Zatsepin and Alexander Lossos and Rafael {\'A}lvarez and Escrib{\'a}, {Pablo V.} and Minassian, {Berge A.} and {Von Delft}, Frank and Or Kakhlon and Yue, {Wyatt W.}",
year = "2015",
month = "6",
day = "5",
doi = "10.1093/hmg/ddv280",
language = "English (US)",
volume = "24",
pages = "5667--5676",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "20",

}

TY - JOUR

T1 - Structural basis of glycogen branching enzyme deficiency and pharmacologic rescue by rational peptide design

AU - Sean Froese, D.

AU - Michaeli, Amit

AU - McCorvie, Thomas J.

AU - Krojer, Tobias

AU - Sasi, Meitav

AU - Melaev, Esther

AU - Goldblum, Amiram

AU - Zatsepin, Maria

AU - Lossos, Alexander

AU - Álvarez, Rafael

AU - Escribá, Pablo V.

AU - Minassian, Berge A.

AU - Von Delft, Frank

AU - Kakhlon, Or

AU - Yue, Wyatt W.

PY - 2015/6/5

Y1 - 2015/6/5

N2 - Glycogen branching enzyme 1 (GBE1) plays an essential role inglycogenbiosynthesis by generating a-1,6-glucosidic branches from α-1,4-linked glucose chains, to increase solubility of the glycogen polymer. Mutations in the GBE1 gene lead to the heterogeneous early-onset glycogen storage disorder type IV (GSDIV) or the late-onset adult polyglucosan body disease (APBD). To better understand this essential enzyme, we crystallized human GBE1 in the apo form, and in complex with a tetra- or hepta-saccharide. The GBE1 structure reveals a conservedamylase core that houses the active centre for the branching reaction and harbours almost all GSDIV andAPBDmutations. Anon-catalytic binding cleft, proximal to the site of the common APBDmutation p.Y329S,was found to bind the tetra- and hepta-saccharides andmay represent a higher-affinity site employed to anchor the complex glycogen substrate for the branching reaction. Expression of recombinant GBE1-p.Y329S resulted in drastically reduced protein yield and solubility compared with wild type, suggesting this disease allele causes protein misfolding and may be amenable to small molecule stabilization. To explore this, we generated a structural model of GBE1-p.Y329S and designed peptides ab initio to stabilize the mutation. As proof-of-principle, we evaluated treatment of one tetra-peptide, Leu-Thr-Lys-Glu, in APBD patient cells. We demonstrate intracellular transport of this peptide, its binding and stabilization of GBE1-p.Y329S, and 2-fold increased mutant enzymatic activity compared with untreated patient cells. Together, our data provide the rationale and starting point for the screening of small molecule chaperones, which could become novel therapies for this disease.

AB - Glycogen branching enzyme 1 (GBE1) plays an essential role inglycogenbiosynthesis by generating a-1,6-glucosidic branches from α-1,4-linked glucose chains, to increase solubility of the glycogen polymer. Mutations in the GBE1 gene lead to the heterogeneous early-onset glycogen storage disorder type IV (GSDIV) or the late-onset adult polyglucosan body disease (APBD). To better understand this essential enzyme, we crystallized human GBE1 in the apo form, and in complex with a tetra- or hepta-saccharide. The GBE1 structure reveals a conservedamylase core that houses the active centre for the branching reaction and harbours almost all GSDIV andAPBDmutations. Anon-catalytic binding cleft, proximal to the site of the common APBDmutation p.Y329S,was found to bind the tetra- and hepta-saccharides andmay represent a higher-affinity site employed to anchor the complex glycogen substrate for the branching reaction. Expression of recombinant GBE1-p.Y329S resulted in drastically reduced protein yield and solubility compared with wild type, suggesting this disease allele causes protein misfolding and may be amenable to small molecule stabilization. To explore this, we generated a structural model of GBE1-p.Y329S and designed peptides ab initio to stabilize the mutation. As proof-of-principle, we evaluated treatment of one tetra-peptide, Leu-Thr-Lys-Glu, in APBD patient cells. We demonstrate intracellular transport of this peptide, its binding and stabilization of GBE1-p.Y329S, and 2-fold increased mutant enzymatic activity compared with untreated patient cells. Together, our data provide the rationale and starting point for the screening of small molecule chaperones, which could become novel therapies for this disease.

UR - http://www.scopus.com/inward/record.url?scp=84943763050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943763050&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddv280

DO - 10.1093/hmg/ddv280

M3 - Article

C2 - 26199317

AN - SCOPUS:84943763050

VL - 24

SP - 5667

EP - 5676

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 20

ER -